SAFETY AND TOLERABILITY OF PIRFENIDONE FOR RESTRICTIVE CHRONIC LUNG ALLOGRAFT DYSFUNCTION (PIRCLAD): INTERIM RESULTS
نویسندگان
چکیده
منابع مشابه
Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
BACKGROUND Bronchiolitis obliterans syndrome (BOS) with small-airway pathology and obstructive pulmonary physiology may not be the only form of chronic lung allograft dysfunction (CLAD) after lung transplantation. Characteristics of a form of CLAD consisting of restrictive functional changes involving peripheral lung pathology were investigated. METHODS Patients who received bilateral lung tr...
متن کاملFeasibility, Safety, and Tolerance of Mesenchymal Stem Cell Therapy for Obstructive Chronic Lung Allograft Dysfunction
Feasibility, tolerance, and safety of intravenous infusions of allogeneic mesenchymal stem cell (MSC) therapy in lung transplant recipients with bronchiolitis obliterans syndrome (BOS) are not well established. MSCs were manufactured, cryopreserved, transported to our facility, thawed, and infused into nine recipients with moderate BOS (average drop in forced expiratory volume in 1 second was 5...
متن کاملChronic lung allograft dysfunction: evolving practice.
PURPOSE OF REVIEW Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term covering different phenotypes of chronic allograft dysfunction, including obstructive CLAD (bronchiolitis obliterans syndrome), restrictive CLAD (restrictive allograft syndrome) and graft dysfunction due to causes not related to chronic rejection. In the present review, we will highlight t...
متن کاملChronic lung allograft dysfunction following lung transplantation: challenges and solutions
متن کامل
Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First‐in‐Man Study
Chronic lung transplant rejection (termed chronic lung allograft dysfunction [CLAD]) is the main impediment to long-term survival after lung transplantation. Bone marrow-derived mesenchymal stromal cells (MSCs) represent an attractive cell therapy in inflammatory diseases, including organ rejection, given their relative immune privilege and immunosuppressive and tolerogenic properties. Preclini...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chest
سال: 2020
ISSN: 0012-3692
DOI: 10.1016/j.chest.2020.08.2028